---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-017472"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T22:15:39.221762+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Intellia dosed first patient in NTLA-2002 Phase 2; Q1 net loss $103.1M, cash $1.2B

## Summary
- Dosed first patient in global Phase 2 study of NTLA-2002 for HAE; enrollment completion expected 2H 2023.
- Plans to submit IND in mid-2023 for global pivotal trial of NTLA-2001 for ATTR-CM; study initiation expected by year-end 2023.
- Cash, cash equivalents and marketable securities of $1.2B as of March 31, 2023; net loss $103.1M for Q1 2023.
- R&D expenses decreased to $97.1M from $133.1M YoY, partially due to absence of Rewrite acquisition expense.
- Collaboration revenue increased to $12.6M from $11.3M; G&A expenses rose to $27.4M.

## SEC filing metadata
- accession: 0000950170-23-017472
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000095017023017472/0000950170-23-017472-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000095017023017472/ntla-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-017472
- JSON: https://secwatch.observer/filing/0000950170-23-017472.json
- Plain text: https://secwatch.observer/filing/0000950170-23-017472.txt

## Key facts
- Earnings Releases
  Intellia Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2023.
  - Period: the first quarter ended March 31, 2023
  - Result: reported results
  source text: CAMBRIDGE, Mass., May 4, 2023 – Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the first quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000095017023017472/0000950170-23-017472-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.